INMB · Inmune Bio, Inc. · Executive Compensation
$0.89
0.00 (-0.47%)
At close · Nov 20
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Going-concern doubt
— flagged Nov 5, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions and events raise substantial doubt about the Company’s ability to continue as a going concern. As a result, the Company has concluded that management’s plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed Nov 5, 2026
Market Cap
$27.68M
Shares
30.96M
Volume · Nov 20
7246
Avg daily vol (3M)
342.92K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Raymond J. Tesi | M.D., former CEO, President and CMO | $2,849,504 |
| David J. Moss | CEO and President | $1,845,179 |
| Mark Lowdell | CSO | $1,452,236 |
| Cory Ellspermann | CFO | $619,227 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Raymond J. Tesi | CEO/President/CMO | $3,008,174 |
| David J. Moss | CFO | $2,722,003 |
| Mark Lowdell | CSO | $1,792,412 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Raymond J. Tesi | CEO/President/CMO | $1,694,818 |
| David J. Moss | CFO | $1,589,218 |
| Mark Lowdell | CSO | $150,237 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Raymond J. Tesi | CEO/President/CMO | $1,444,509 |
| David J. Moss | CFO | $1,298,169 |
| Mark Lowdell | CSO | $904,599 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Raymond J. Tesi | CEO/President/CMO | $2,702,228 |
| David J. Moss | CFO | $2,631,228 |
| Mark Lowdell | CSO | $149,478 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| David J. Moss | CFO | $300,000 |
| Raymond J. Tesi | CEO/President/CMO | $300,000 |
| Mark Lowdell | CSO | $138,204 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| James Sapirstein | members of the Nominating and Corporate Governance Committee of the Board | Appointed | 2026-09-14 |
| James Sapirstein | directors of the Company | Appointed | 2026-09-14 |
| R. Duane Clark II | members of the Nominating and Corporate Governance Committee of the Board | Appointed | 2026-09-14 |
| R. Duane Clark II | directors of the Company | Appointed | 2026-09-14 |
| Scott Juda, JD | Director | Appointed | 2026-06-17 |
| Marcia Allen | Director |
Already on the board
Since at least 2019: re-election or new board role
|
2026-06-17 |
| Tim Schroeder | Director |
Already on the board
Since at least 2016: re-election or new board role
|
2026-06-17 |
| J. Kelly Ganjei | Director |
Already on the board
Since at least 2016: re-election or new board role
|
2026-06-17 |
| David Moss | Director | Appointed | 2026-06-17 |
| Cory Ellspermann | Chief Financial Officer | Appointed | 2025-11-28 |
| Marcia Allen | Director |
Already on the board
Since at least 2019: re-election or new board role
|
2025-06-10 |
| Tim Schroeder | Director |
Already on the board
Since at least 2016: re-election or new board role
|
2025-06-10 |
| Scott Juda, JD | Director | Appointed | 2025-06-10 |
| J. Kelly Ganjei | Director |
Already on the board
Since at least 2016: re-election or new board role
|
2025-06-10 |
| Raymond J. Tesi, MD | Director | Appointed | 2025-06-10 |
|
Edgardo Baracchini
“Mr. Baracchini’s resignation was not the result of any disagreement relating to the Company’s policies, operations or practices.”
|
board of directors | Resigned | 2024-07-05 |
| Marcia Allen | Director |
Already on the board
Since at least 2019: re-election or new board role
|
2023-06-01 |
| Edgardo Baracchini, PhD | Director | Appointed | 2023-06-01 |
| Scott Juda, JD | Director | Appointed | 2023-06-01 |
| Tim Schroeder | Director |
Already on the board
Since at least 2016: re-election or new board role
|
2023-06-01 |
| J. Kelly Ganjei | Director |
Already on the board
Since at least 2016: re-election or new board role
|
2023-06-01 |
| Raymond J. Tesi, MD | Director | Appointed | 2023-06-01 |
|
David Szymkowski, Ph.D.
“Mr. Szymkowski did not advise the Company of any disagreement with the Company on any matter relating to its operations, policies or practices.”
|
Board of Directors | Resigned | 2021-06-15 |
|
David Szymkowski
“Mr. Szymkowski did not advise the Company of any disagreement with the Company on any matter relating to its operations, policies or practices.”
|
member of the board of directors | Resigned | 2021-06-15 |
Leadership
- David J. Moss CEO, Board Member
- J. Kelly Ganjei Chairman
- Cory Ellspermann Board Member
- David Moss Board Member
- Edgardo Baracchini, PhD Board Member
- James Sapirstein Board Member
- Marcia Allen Board Member
- Mark Lowdell Board Member
- R. Duane Clark II Board Member
- Raymond J. Tesi, MD Board Member
- Scott Juda Board Member
- Scott Juda, JD Board Member
- Timothy Schroeder Board Member
Key facts
CIK
1711754
CUSIP
45782T105
13F (30d)
70 filings
58 filers
Visit website
Investor relations